Barcoded bulk QTL mapping reveals highly polygenic and epistatic architecture of complex traits in yeast. Elife. 2022 Feb 11; 11.
View in:
PubMed
Transcriptional differences between JAK2-V617F and wild-type bone marrow cells in patients with myeloproliferative neoplasms. Exp Hematol. 2022 Mar; 107:14-19.
View in:
PubMed
Response to comment on "Genomic epidemiology of superspreading events in Austria reveals mutational dynamics and transmission properties of SARS-CoV-2". Sci Transl Med. 2021 Oct 27; 13(617):eabj3222.
View in:
PubMed
Systematic tissue collection during clinical breast biopsy is feasible, safe and enables high-content translational analyses. NPJ Precis Oncol. 2021 Sep 21; 5(1):85.
View in:
PubMed
Dissecting dual roles of MyoD during lineage conversion to mature myocytes and myogenic stem cells. Genes Dev. 2021 09 01; 35(17-18):1209-1228.
View in:
PubMed
Topological isolation of developmental regulators in mammalian genomes. Nat Commun. 2021 08 12; 12(1):4897.
View in:
PubMed
Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer. Nat Commun. 2021 06 17; 12(1):3697.
View in:
PubMed
The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancer. JCI Insight. 2021 06 08; 6(11).
View in:
PubMed
Combined epigenetic and metabolic treatments overcome differentiation blockade in acute myeloid leukemia. iScience. 2021 Jun 25; 24(6):102651.
View in:
PubMed
Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab. Cancer Discov. 2021 10; 11(10):2474-2487.
View in:
PubMed
Progression signature underlies clonal evolution and dissemination of multiple myeloma. Blood. 2021 04 29; 137(17):2360-2372.
View in:
PubMed
Computational modelling of perivascular-niche dynamics for the optimization of treatment schedules for glioblastoma. Nat Biomed Eng. 2021 04; 5(4):346-359.
View in:
PubMed
Breast tumours maintain a reservoir of subclonal diversity during expansion. Nature. 2021 04; 592(7853):302-308.
View in:
PubMed
A Quantitative Paradigm for Decision-Making in Precision Oncology. Trends Cancer. 2021 04; 7(4):293-300.
View in:
PubMed
Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms. Cell Stem Cell. 2021 03 04; 28(3):514-523.e9.
View in:
PubMed
How Does Large-Scale Genomic Analysis Shape Our Understanding of COVID Variants in Real Time? Cell Syst. 2021 02 17; 12(2):109-111.
View in:
PubMed
Imaging dynamic mTORC1 pathway activity in vivo reveals marked shifts that support time-specific inhibitor therapy in AML. Nat Commun. 2021 01 11; 12(1):245.
View in:
PubMed
Genomic epidemiology of superspreading events in Austria reveals mutational dynamics and transmission properties of SARS-CoV-2. Sci Transl Med. 2020 12 09; 12(573).
View in:
PubMed
Circadian clock effects on cellular proliferation: Insights from theory and experiments. Curr Opin Cell Biol. 2020 12; 67:17-26.
View in:
PubMed
ESTIpop: a computational tool to simulate and estimate parameters for continuous-time Markov branching processes. Bioinformatics. 2020 08 01; 36(15):4372-4373.
View in:
PubMed
Pharmacokinetic Profiles Determine Optimal Combination Treatment Schedules in Computational Models of Drug Resistance. Cancer Res. 2020 08 15; 80(16):3372-3382.
View in:
PubMed
Accelerating massively parallel hemodynamic models of coarctation of the aorta using neural networks. Sci Rep. 2020 06 11; 10(1):9508.
View in:
PubMed
Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer. Mol Cell. 2020 06 18; 78(6):1096-1113.e8.
View in:
PubMed
Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer. Nat Commun. 2020 05 11; 11(1):2350.
View in:
PubMed
Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations. Cancer Res. 2020 05 15; 80(10):2017-2030.
View in:
PubMed
Ascl2-Dependent Cell Dedifferentiation Drives Regeneration of Ablated Intestinal Stem Cells. Cell Stem Cell. 2020 03 05; 26(3):377-390.e6.
View in:
PubMed
DIFFpop: a stochastic computational approach to simulate differentiation hierarchies with single cell barcoding. Bioinformatics. 2019 10 01; 35(19):3849-3851.
View in:
PubMed
Mathematical modeling reveals alternative JAK inhibitor treatment in myeloproliferative neoplasms. Haematologica. 2020 03; 105(3):e91-e94.
View in:
PubMed
Subclonal cooperation drives metastasis by modulating local and systemic immune microenvironments. Nat Cell Biol. 2019 07; 21(7):879-888.
View in:
PubMed
Computational modeling of pancreatic cancer patients receiving FOLFIRINOX and gemcitabine-based therapies identifies optimum intervention strategies. PLoS One. 2019; 14(4):e0215409.
View in:
PubMed
Stochastic Evolution of Pancreatic Cancer Metastases During Logistic Clonal Expansion. JCO Clin Cancer Inform. 2019 03; 3:1-11.
View in:
PubMed
KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance. Cancer Cell. 2019 Feb 11; 35(2):330-332.
View in:
PubMed
Hidden heterogeneity and circadian-controlled cell fate inferred from single cell lineages. Nat Commun. 2018 12 18; 9(1):5372.
View in:
PubMed
Computational Model of Progression to Multiple Myeloma Identifies Optimum Screening Strategies. JCO Clin Cancer Inform. 2018 12; 2:1-12.
View in:
PubMed
Currently available bulk sequencing data do not necessarily support a model of neutral tumor evolution. Nat Genet. 2018 12; 50(12):1620-1623.
View in:
PubMed
KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance. Cancer Cell. 2018 12 10; 34(6):939-953.e9.
View in:
PubMed
Fitness variation in isogenic populations leads to a novel evolutionary mechanism for crossing fitness valleys. Commun Biol. 2018; 1:151.
View in:
PubMed
Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq. Nat Commun. 2018 09 04; 9(1):3588.
View in:
PubMed
A PDGFRa-driven mouse model of glioblastoma reveals a stathmin1-mediated mechanism of sensitivity to vinblastine. Nat Commun. 2018 08 06; 9(1):3116.
View in:
PubMed
Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer. NPJ Breast Cancer. 2018; 4:10.
View in:
PubMed
Increased HOXA5 expression provides a selective advantage for gain of whole chromosome 7 in IDH wild-type glioblastoma. Genes Dev. 2018 04 01; 32(7-8):512-523.
View in:
PubMed
Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients. PLoS Comput Biol. 2018 01; 14(1):e1005924.
View in:
PubMed
The Warburg effect: persistence of stem-cell metabolism in cancers as a failure of differentiation. Ann Oncol. 2018 01 01; 29(1):264-270.
View in:
PubMed
Nuclear topology modulates the mutational landscapes of cancer genomes. Nat Struct Mol Biol. 2017 Nov; 24(11):1000-1006.
View in:
PubMed
mTOR and HDAC Inhibitors Converge on the TXNIP/Thioredoxin Pathway to Cause Catastrophic Oxidative Stress and Regression of RAS-Driven Tumors. Cancer Discov. 2017 12; 7(12):1450-1463.
View in:
PubMed
Epigenetic restriction of extraembryonic lineages mirrors the somatic transition to cancer. Nature. 2017 09 28; 549(7673):543-547.
View in:
PubMed
Analysis of somatic microsatellite indels identifies driver events in human tumors. Nat Biotechnol. 2017 Oct; 35(10):951-959.
View in:
PubMed
Estimating mono- and bi-phasic regression parameters using a mixture piecewise linear Bayesian hierarchical model. PLoS One. 2017; 12(7):e0180756.
View in:
PubMed
SIApopr: a computational method to simulate evolutionary branching trees for analysis of tumor clonal evolution. Bioinformatics. 2017 Jul 15; 33(14):2221-2223.
View in:
PubMed
Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition. Cancer Discov. 2017 10; 7(10):1098-1115.
View in:
PubMed
Bisulfite-independent analysis of CpG island methylation enables genome-scale stratification of single cells. Nucleic Acids Res. 2017 Jun 02; 45(10):e77.
View in:
PubMed
Pharmacokinetics and Drug Interactions Determine Optimum Combination Strategies in Computational Models of Cancer Evolution. Cancer Res. 2017 07 15; 77(14):3908-3921.
View in:
PubMed
The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma. Cell Rep. 2017 04 04; 19(1):218-224.
View in:
PubMed
Mathematical Modeling Links Pregnancy-Associated Changes and Breast Cancer Risk. Cancer Res. 2017 06 01; 77(11):2800-2809.
View in:
PubMed
Distance in cancer gene expression from stem cells predicts patient survival. PLoS One. 2017; 12(3):e0173589.
View in:
PubMed
Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers. Ann Oncol. 2017 02 01; 28(2):278-284.
View in:
PubMed
Proceedings of the third international molecular pathological epidemiology (MPE) meeting. Cancer Causes Control. 2017 02; 28(2):167-176.
View in:
PubMed
Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. J Clin Oncol. 2017 May 10; 35(14):1598-1605.
View in:
PubMed
Probabilistic Modeling of Reprogramming to Induced Pluripotent Stem Cells. Cell Rep. 2016 12 20; 17(12):3395-3406.
View in:
PubMed
A computational strategy to adjust for copy number in tumor Hi-C data. Bioinformatics. 2016 12 15; 32(24):3695-3701.
View in:
PubMed
Punctuated copy number evolution and clonal stasis in triple-negative breast cancer. Nat Genet. 2016 10; 48(10):1119-30.
View in:
PubMed
ABCG2 regulates self-renewal and stem cell marker expression but not tumorigenicity or radiation resistance of glioma cells. Sci Rep. 2016 07 26; 6:25956.
View in:
PubMed
Mathematical modeling of erythrocyte chimerism informs genetic intervention strategies for sickle cell disease. Am J Hematol. 2016 09; 91(9):931-7.
View in:
PubMed
Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution. Clin Cancer Res. 2016 Aug 15; 22(16):4206-4214.
View in:
PubMed
The mathematics of cancer: integrating quantitative models. Nat Rev Cancer. 2015 Dec; 15(12):730-45.
View in:
PubMed
Improving Cancer Treatment via Mathematical Modeling: Surmounting the Challenges Is Worth the Effort. Cell. 2015 Nov 19; 163(5):1059-1063.
View in:
PubMed
Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer Patients. PLoS One. 2015; 10(11):e0141665.
View in:
PubMed
An Evolutionary Approach for Identifying Driver Mutations in Colorectal Cancer. PLoS Comput Biol. 2015 Sep; 11(9):e1004350.
View in:
PubMed
In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer. Nat Genet. 2015 Oct; 47(10):1212-9.
View in:
PubMed
CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation. Cell Rep. 2015 Jul 28; 12(4):622-35.
View in:
PubMed
The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells. Cancer Inform. 2015; 14(Suppl 4):19-31.
View in:
PubMed
Optimization of radiation dosing schedules for proneural glioblastoma. J Math Biol. 2016 Apr; 72(5):1301-36.
View in:
PubMed
Studying clonal dynamics in response to cancer therapy using high-complexity barcoding. Nat Med. 2015 May; 21(5):440-8.
View in:
PubMed
DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors. BMC Cancer. 2015 Apr 09; 15:242.
View in:
PubMed
Polyploidy can drive rapid adaptation in yeast. Nature. 2015 Mar 19; 519(7543):349-52.
View in:
PubMed
Stochastic tunneling and metastable states during the somatic evolution of cancer. Genetics. 2015 Apr; 199(4):1213-28.
View in:
PubMed
JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer Discov. 2015 Mar; 5(3):316-31.
View in:
PubMed
Epigenetic diversity in hematopoietic neoplasms. Biochim Biophys Acta. 2014 Dec; 1846(2):477-84.
View in:
PubMed
Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib. Haematologica. 2014 Nov; 99(11):1701-9.
View in:
PubMed
Most human non-GCIMP glioblastoma subtypes evolve from a common proneural-like precursor glioma. Cancer Cell. 2014 Aug 11; 26(2):288-300.
View in:
PubMed
Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity. Nature. 2014 Oct 02; 514(7520):54-8.
View in:
PubMed
Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature. 2014 Aug 14; 512(7513):155-60.
View in:
PubMed
On the validity of using increases in 5-year survival rates to measure success in the fight against cancer. PLoS One. 2014; 9(7):e83100.
View in:
PubMed
Histone modifications are associated with transcript isoform diversity in normal and cancer cells. PLoS Comput Biol. 2014 Jun; 10(6):e1003611.
View in:
PubMed
FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. Cancer Med. 2014 Aug; 3(4):835-44.
View in:
PubMed
Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. J Natl Cancer Inst. 2014 Apr 03; 106(5).
View in:
PubMed
Understanding tissue context influences on intratumour heterogeneity. Nat Cell Biol. 2014 Apr; 16(4):301-2.
View in:
PubMed
Evolution of acquired resistance to anti-cancer therapy. J Theor Biol. 2014 Aug 21; 355:10-20.
View in:
PubMed
Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma. Clin Cancer Res. 2014 Apr 01; 20(7):1873-83.
View in:
PubMed
Mathematical modeling of PDGF-driven glioblastoma reveals optimized radiation dosing schedules. Cell. 2014 Jan 30; 156(3):603-616.
View in:
PubMed
Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. Cell Rep. 2014 Feb 13; 6(3):514-27.
View in:
PubMed
Genetic and phenotypic diversity in breast tumor metastases. Cancer Res. 2014 Mar 01; 74(5):1338-48.
View in:
PubMed
Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes. Blood. 2014 Mar 13; 123(11):1699-708.
View in:
PubMed
Safety and efficacy of pulsed imatinib with or without G-CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up. Br J Haematol. 2013 Dec; 163(5):674-6.
View in:
PubMed
Stochastic Tunneling of Two Mutations in a Population of Cancer Cells. PLoS One. 2013; 8(6):e65724.
View in:
PubMed
Patterns of proliferative activity in the colonic crypt determine crypt stability and rates of somatic evolution. PLoS Comput Biol. 2013; 9(6):e1003082.
View in:
PubMed
Molecular profiling of human mammary gland links breast cancer risk to a p27(+) cell population with progenitor characteristics. Cell Stem Cell. 2013 Jul 03; 13(1):117-30.
View in:
PubMed
Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance. Genome Res. 2013 Sep; 23(9):1434-45.
View in:
PubMed
Genomic characterization of metastatic urothelial carcinoma. J Clin Oncol. 2013 Feb 20; 31(6_suppl):247.
View in:
PubMed
Peroxisome proliferator-activated receptor gamma (PPARG) gene amplifications in urothelial carcinoma (UC). J Clin Oncol. 2013 Feb 20; 31(6_suppl):279.
View in:
PubMed
Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J Clin Oncol. 2013 Mar 10; 31(8):1070-80.
View in:
PubMed
Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity. PLoS Genet. 2013; 9(1):e1003137.
View in:
PubMed
DNA replication timing and higher-order nuclear organization determine single-nucleotide substitution patterns in cancer genomes. Nat Commun. 2013; 4:1502.
View in:
PubMed
A physical sciences network characterization of non-tumorigenic and metastatic cells. Sci Rep. 2013; 3:1449.
View in:
PubMed
Analyzing the association of SCNA boundaries with replication timing. Nat Biotechnol. 2012 Nov; 30(11):1045-6.
View in:
PubMed
Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancer. J Thorac Oncol. 2012 Oct; 7(10):1583-93.
View in:
PubMed
Evolutionary pathways in BRCA1-associated breast tumors. Cancer Discov. 2012 Jun; 2(6):503-11.
View in:
PubMed
Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials. Haematologica. 2012 Oct; 97(10):1553-61.
View in:
PubMed
Evolution of the cancer genome. Trends Genet. 2012 Apr; 28(4):155-63.
View in:
PubMed
A race between tumor immunoescape and genome maintenance selects for optimum levels of (epi)genetic instability. PLoS Comput Biol. 2012; 8(2):e1002370.
View in:
PubMed
Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell. 2012 Jan 20; 148(1-2):362-75.
View in:
PubMed
Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer. Clin Cancer Res. 2012 Mar 01; 18(5):1323-33.
View in:
PubMed
A mathematical methodology for determining the temporal order of pathway alterations arising during gliomagenesis. PLoS Comput Biol. 2012 Jan; 8(1):e1002337.
View in:
PubMed
Fitness conferred by BCR-ABL kinase domain mutations determines the risk of pre-existing resistance in chronic myeloid leukemia. PLoS One. 2011; 6(11):e27682.
View in:
PubMed
DNA replication timing and long-range DNA interactions predict mutational landscapes of cancer genomes. Nat Biotechnol. 2011 Nov 20; 29(12):1103-8.
View in:
PubMed
Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer. Mol Pharm. 2011 Dec 05; 8(6):2069-79.
View in:
PubMed
The probable cell of origin of NF1- and PDGF-driven glioblastomas. PLoS One. 2011; 6(9):e24454.
View in:
PubMed
What does physics have to do with cancer? Nat Rev Cancer. 2011 Aug 18; 11(9):657-70.
View in:
PubMed
DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation. Blood. 2011 Sep 29; 118(13):3559-69.
View in:
PubMed
Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med. 2011 Jul 06; 3(90):90ra59.
View in:
PubMed
DNA secondary structures and epigenetic determinants of cancer genome evolution. Nat Struct Mol Biol. 2011 Jul 03; 18(8):950-5.
View in:
PubMed
Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells. Blood. 2011 Aug 11; 118(6):1622-31.
View in:
PubMed
A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature. 2011 May 12; 473(7346):230-3.
View in:
PubMed
Evolutionary dynamics of intratumor heterogeneity. PLoS One. 2011 Mar 30; 6(3):e17866.
View in:
PubMed
Intratumor heterogeneity in evolutionary models of tumor progression. Genetics. 2011 Jun; 188(2):461-77.
View in:
PubMed
Stochastic dynamics of cancer initiation. Phys Biol. 2011 Feb; 8(1):015002.
View in:
PubMed
Evolutionary dynamics of BRCA1 alterations in breast tumorigenesis. J Theor Biol. 2011 Mar 21; 273(1):207-15.
View in:
PubMed
The therapeutic implications of plasticity of the cancer stem cell phenotype. PLoS One. 2010 Dec 17; 5(12):e14366.
View in:
PubMed
The origins and implications of intratumor heterogeneity. Cancer Prev Res (Phila). 2010 Nov; 3(11):1361-4.
View in:
PubMed
A mathematical framework to determine the temporal sequence of somatic genetic events in cancer. Proc Natl Acad Sci U S A. 2010 Oct 12; 107(41):17604-9.
View in:
PubMed
A differentiation-based microRNA signature identifies leiomyosarcoma as a mesenchymal stem cell-related malignancy. Am J Pathol. 2010 Aug; 177(2):908-17.
View in:
PubMed
Evolutionary dynamics of tumor progression with random fitness values. Theor Popul Biol. 2010 Aug; 78(1):54-66.
View in:
PubMed
A differentiation-based phylogeny of cancer subtypes. PLoS Comput Biol. 2010 May 06; 6(5):e1000777.
View in:
PubMed
Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. J Clin Invest. 2010 Feb; 120(2):636-44.
View in:
PubMed
Evolution of resistance to anti-cancer therapy during general dosing schedules. J Theor Biol. 2010 Mar 21; 263(2):179-88.
View in:
PubMed
The evolution of tumor metastases during clonal expansion. J Theor Biol. 2010 Mar 07; 263(1):30-44.
View in:
PubMed
Evolution of resistance to targeted anti-cancer therapies during continuous and pulsed administration strategies. PLoS Comput Biol. 2009 Nov; 5(11):e1000557.
View in:
PubMed
A progenitor cell origin of myeloid malignancies. Proc Natl Acad Sci U S A. 2009 Sep 29; 106(39):16616-21.
View in:
PubMed
Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib. PLoS Comput Biol. 2009 Sep; 5(9):e1000503.
View in:
PubMed
Evolutionary theory of cancer. Ann N Y Acad Sci. 2009 Jun; 1168:23-51.
View in:
PubMed
A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1). Haematologica. 2008 Aug; 93(8):1219-26.
View in:
PubMed
Mathematical models of cancer stem cells. J Clin Oncol. 2008 Jun 10; 26(17):2854-61.
View in:
PubMed
The evolution of two mutations during clonal expansion. Genetics. 2007 Dec; 177(4):2209-21.
View in:
PubMed
Quantitative approaches to analyzing imatinib-treated chronic myeloid leukemia. Trends Pharmacol Sci. 2007 May; 28(5):197-9.
View in:
PubMed
The emergence of tumor metastases. Cancer Biol Ther. 2007 Mar; 6(3):383-90.
View in:
PubMed
(A)symmetric stem cell replication and cancer. PLoS Comput Biol. 2007 Mar 16; 3(3):e53.
View in:
PubMed
Chronic myeloid leukemia blast crisis arises from progenitors. Stem Cells. 2007 May; 25(5):1114-8.
View in:
PubMed
Mathematical models of targeted cancer therapy. Br J Cancer. 2006 Nov 06; 95(9):1136-41.
View in:
PubMed
The age incidence of chronic myeloid leukemia can be explained by a one-mutation model. Proc Natl Acad Sci U S A. 2006 Oct 03; 103(40):14931-4.
View in:
PubMed
Successful therapy must eradicate cancer stem cells. Stem Cells. 2006 Dec; 24(12):2603-10.
View in:
PubMed
Evolution of resistance during clonal expansion. Genetics. 2006 Apr; 172(4):2557-66.
View in:
PubMed
Dynamics of metastasis suppressor gene inactivation. J Theor Biol. 2006 Aug 07; 241(3):676-89.
View in:
PubMed
Genetic instability and clonal expansion. J Theor Biol. 2006 Jul 07; 241(1):26-32.
View in:
PubMed
Genetic instability and the quasispecies model. J Theor Biol. 2006 Jul 21; 241(2):216-22.
View in:
PubMed
Evolution of resistance to cancer therapy. Curr Pharm Des. 2006; 12(3):261-71.
View in:
PubMed
Stochastic dynamics of metastasis formation. J Theor Biol. 2006 Jun 21; 240(4):521-30.
View in:
PubMed
Dynamics of colorectal cancer. Semin Cancer Biol. 2005 Dec; 15(6):484-93.
View in:
PubMed
Synergy and discounting of cooperation in social dilemmas. J Theor Biol. 2006 Mar 21; 239(2):195-202.
View in:
PubMed
Dynamics of chronic myeloid leukaemia. Nature. 2005 Jun 30; 435(7046):1267-70.
View in:
PubMed
Chromosomal instability and human cancer. Philos Trans R Soc Lond B Biol Sci. 2005 Mar 29; 360(1455):631-5.
View in:
PubMed
Can chromosomal instability initiate tumorigenesis? Semin Cancer Biol. 2005 Feb; 15(1):43-9.
View in:
PubMed
Virus evolution within patients increases pathogenicity. J Theor Biol. 2005 Jan 07; 232(1):17-26.
View in:
PubMed
Population genetics of tumor suppressor genes. J Theor Biol. 2005 Mar 07; 233(1):15-23.
View in:
PubMed
Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response. J Exp Med. 2004 Nov 15; 200(10):1243-56.
View in:
PubMed
Some basic properties of immune selection. J Theor Biol. 2004 Jul 21; 229(2):179-88.
View in:
PubMed
Evolutionary dynamics of tumor suppressor gene inactivation. Proc Natl Acad Sci U S A. 2004 Jul 20; 101(29):10635-8.
View in:
PubMed
Linear model of colon cancer initiation. Cell Cycle. 2004 Mar; 3(3):358-62.
View in:
PubMed
Dynamics of cancer progression. Nat Rev Cancer. 2004 Mar; 4(3):197-205.
View in:
PubMed
Stochastic tunnels in evolutionary dynamics. Genetics. 2004 Mar; 166(3):1571-9.
View in:
PubMed
Evolutionary dynamics of invasion and escape. J Theor Biol. 2004 Jan 21; 226(2):205-14.
View in:
PubMed
Evolutionary dynamics of escape from biomedical intervention. Proc Biol Sci. 2003 Dec 22; 270(1533):2573-8.
View in:
PubMed
Somatic selection for and against cancer. J Theor Biol. 2003 Dec 07; 225(3):377-82.
View in:
PubMed
The linear process of somatic evolution. Proc Natl Acad Sci U S A. 2003 Dec 09; 100(25):14966-9.
View in:
PubMed
Stochastic elimination of cancer cells. Proc Biol Sci. 2003 Oct 07; 270(1528):2017-24.
View in:
PubMed
Local regulation of homeostasis favors chromosomal instability. Curr Biol. 2003 Apr 01; 13(7):581-4.
View in:
PubMed
Evolution: the good, the bad and the lonely. Nature. 2002 Oct 17; 419(6908):677, 679.
View in:
PubMed